Business
Mdxhealth files U.S. Shelf Registration on Form F-3
NEWS RELEASE – REGULATED INFORMATIONDecember 19, 2022, 5:00PM EDT / 23:00 CET Mdxhealth files U.S. Shelf Registration on Form F-3 IRVINE, CA, and HERSTAL,
About this update from Mdxhealth Sa
[{"type":"text","content":"NEWS RELEASE – REGULATED INFORMATIONDecember 19, 2022, 5:00PM EDT / 23:00 CET Mdxhealth files U.S. Shelf Registration on Form F-3 IRVINE, CA, and HERSTAL, BELGIUM – December 19, 2022 – Mdxhealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that it has filed a U.S. “shelf” registration statement for its American Depositary Shares (“ADSs”), each representing 10 ordinary shares. The Company filed the shelf registration statement and associated financial information as a matter of standard corporate procedure for NASDAQ-listed companies and to streamline any response to future strategic or financing needs. If declared effective, the shelf registration statement may remain available for up to three years. About mdxhealth® Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California, with additional laboratory operations in Plano, Texas. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth. For more information: mdxhealth [email protected] LifeSci Advisors (IR & PR)US: +1 949 271 [email protected] This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding the acquisition of Oncotype DX® GPS prostate cancer business from Exact Sciences including statements regarding the an...